NCT00195819

Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
BIOLOGICAL	adalimumab (D2E7)	Adalimumab 40 mg every other week (eow)
BIOLOGICAL	placebo	Placebo every other week (eow)

Timeline

• Start date: 2003-12-01
• Primary completion: 2004-10-01
• Completion: 2009-06-01
• First posted: 2005-09-20
• Last updated: 2011-06-28
• Results posted: 2010-04-28

Locations

9 sites across 1 country: Canada